Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Response Biomedical has entered into an agreement granting rights to Roche Diagnostics to market its line of cardiovascular point-of-care tests worldwide.
Subscribe to our email newsletter
The RAMP cardiovascular product line includes Troponin I, CK-MB, Myoglobin and NT-proBNP Tests. The company is awaiting FDA 510(k) clearance before the NT-proBNP Test can be sold in the US.
Roche Diagnostics’ comprehensive sales and marketing infrastructure is expected to allow for broad worldwide penetration of Response Biomedical’s cardiovascular line.
Wayne Kay, CEO of Response Biomedical, said: “This collaboration significantly enhances our commercialization strategy and sets the stage for rapid market expansion. Furthermore, we are exploring the application of our proprietary RAMP platform to other clinical areas where its unique advantages can be leveraged to improve patient care.”